Menu Search Icon

Search

Division of Endocrinology & Metabolism

Leon Farhi, PhD

Leon Farhi PhDPRIMARY APPOINTMENT:

Associate Professor of Research, Medicine: Endocrinology and Metabolism

CONTACT:

UVA Division of Endocrinology & Metabolism
PO Box 801405
Charlottesville, VA 22908
Telephone: 434-924-2496
Email: lsf8n@virginia.edu

RESEARCH INTERESTS:
Understanding the mechanisms that regulate glucagon secretion, glucose homeostasis, and growth hormone release. Mathematical modeling of hormone networks. Diabetes, hypoglycemia, artificial pancreas technology.

RESEARCH SUMMARY:
My research is in the field of systems endocrinology and focuses on the endocrine mechanisms and relationships between the different cell types in the islets of Langerhans that direct the time-varying secretion patterns of the pancreatic hormones. We are interested in the mechanisms of glucagon release from the T-cells in response to hypoglycemia, study how these mechanisms are altered in diabetes, and seek to develop strategies for their repair. Through a series of interdisciplinary experimental and clinical in vivo work and mathematical modeling in silico studies, we have shown that the abnormalities in the glucagon defenses against hypoglycemia in diabetes are mediated in part by miscommunication between the different cell types in the pancreatic islets and are essential of “network origin.” The lack of T-cell signaling is the primary deficiency that contributes to two separate network defects: (i) absence of a “switch-off” trigger to the T-cells and (ii) increased intraislet basal glucagon. We have experimental evidence suggesting that both defects can be potentially repaired by therapeutic strategies based on T-cell inhibiting drugs.

To further test the hypothesis that T-cell inhibitors can be used to manipulate the pancreatic network to enhance the glucagon response to hypoglycemia and start translating our findings into the clinic, our lab collaborates with the UVA Center for Diabetes Technology. Taking advantage of the Center’s cutting-edge artificial pancreas technologies, we work on the development of strategies for dual-hormone automated glucose control in patients with type 1 diabetes that use both insulin and T-cell inhibiting drugs. Adding a T-cell inhibitor as a second control mechanism will allow us to manipulate the pancreatic endocrine network to achieve better glycemic control with reduced hypoglycemia risk.

In This Section down-arrow
Menu
DEPARTMENT OF MEDICINE